RCAR
RenovaCare, Inc. [RCAR] Stock Forecast
Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000
RCAR Stock Summary
In the News
RCAR Financial details
Company Rating
Buy
Market Cap
8.74K
Income
0
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
1
Optionable
No
Shortable
Yes
Earnings
18 Nov 2022
P/E
0
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
-
P/FCF
-
Quick Ratio
2.18
Current Ratio
2.59
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
0
EPS next Y
-
EPS next Q
-
EPS this Y
-
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-
SMA100
-
Inst Own
0.01%
Inst Trans
2%
ROA
-122%
ROE
-95%
ROC
-2.3%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
1.0E-4-0.35
52W High
-
52W Low
-
RSI
57.54
Rel Volume
6.09
Avg Volume
399
Volume
2.43K
Perf Week
-
Perf Month
-
Perf Quarter
-
Perf Half Y
0%
-
-
-
-
Beta
24.116
-
-
Volatility
0%, 0%
Prev Close
0%
Price
0.0001
Change
0%
RCAR Financial Performance
Yearly Fundamentals Overview
Last date of statement is 2022-12-31
| Metric | History | 2018-12-31 | 2019-12-31 | 2020-12-31 | 2021-12-31 | 2022-12-31 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | -0.03 | -0.04 | -0.11 | -0.05 | 0 | |
| Operating cash flow per share | -0.03 | -0.04 | -0.05 | -0.05 | 0 | |
| Free cash flow per share | -0.03 | -0.04 | -0.05 | -0.05 | 0 | |
| Cash per share | 0.2 | 0.14 | 0.08 | 0.03 | 0 | |
| Book value per share | 0.2 | 0.14 | 0.08 | 0.03 | 0 | |
| Tangible book value per share | 0.2 | 0.14 | 0.08 | 0.03 | 0 | |
| Share holders equity per share | 0.2 | 0.14 | 0.08 | 0.03 | 0 | |
| Interest debt per share | 0 | 0 | 0 | 0 | 0 | |
| Market cap | 112.74M | 279.16M | 244.59M | 24.41M | 0 | |
| Enterprise value | 97.34M | 266.97M | 237.25M | 21.6M | 0 | |
| P/E ratio | -53.16 | -83.13 | -25.97 | -5.47 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -55.64 | -86.9 | -51.79 | -5.35 | 0 | |
| PFCF ratio | -55.64 | -86.9 | -51.34 | -5.35 | 0 | |
| P/B Ratio | 7.36 | 22.96 | 34.55 | 10.4 | 0 | |
| PTB ratio | 7.36 | 22.96 | 34.55 | 10.4 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -49.03 | -79.51 | -24.57 | -4 | 0 | |
| EV to operating cash flow | -48.04 | -83.11 | -50.23 | -4.73 | 0 | |
| EV to free cash flow | -48.04 | -83.11 | -49.8 | -4.73 | 0 | |
| Earnings yield | -0.02 | -0.01 | -0.04 | -0.18 | 0 | |
| Free cash flow yield | -0.02 | -0.01 | -0.02 | -0.19 | 0 | |
| Debt to equity | 0 | 0 | 0.01 | 0.01 | 0 | |
| Debt to assets | 0 | 0 | 0.01 | 0.01 | 0 | |
| Net debt to EBITDA | 7.76 | 3.63 | 0.76 | 0.52 | 0 | |
| Current ratio | 39.64 | 43.77 | 6.19 | 2.59 | 0 | |
| Interest coverage | -14.84 | 0 | 0 | 0 | 0 | |
| Income quality | 0.96 | 0.96 | 0.49 | 1.02 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0.01 | 0.01 | 0.02 | 0.04 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0.01 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | -1.87 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.35 | 0.35 | 0.44 | 0.18 | 0 | |
| ROIC | -0.13 | -0.3 | -1.32 | -2.24 | 0 | |
| Return on tangible assets | -0.14 | -0.27 | -1.14 | -1.28 | 0 | |
| Graham Net | 0.19 | 0.14 | 0.07 | 0.02 | 0 | |
| Working capital | 15.17M | 12.01M | 6.69M | 2.08M | 0 | |
| Tangible asset value | 15.17M | 12.01M | 6.93M | 2.19M | 0 | |
| Net current asset value | 15.17M | 12.01M | 6.66M | 2.08M | 0 | |
| Invested capital | 0 | 0 | 0.01 | 0.01 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 196.92K | 252.95K | 759.09K | 734.63K | 115.91K | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 388.14K | 20.51K | 7.71K | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0.02 | 0.05 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.14 | -0.28 | -1.33 | -1.9 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
Quarterly Fundamentals Overview
Last date of statement is 2023-09-30 for Q3
| Metric | History | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 |
|---|---|---|---|---|---|---|
| 2.02K | 2.02K | 2.02K | 2.02K | 2.02K | ||
| Revenue per share | 0 | 0 | 0 | 0 | 0 | |
| Net income per share | 0.01 | 0 | 0 | 0 | 0 | |
| Operating cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Free cash flow per share | 0 | 0 | 0 | 0 | 0 | |
| Cash per share | 0 | 0 | 0 | 0 | 0 | |
| Book value per share | -0.02 | 0 | 0 | 0 | 0 | |
| Tangible book value per share | -0.02 | 0 | 0 | 0 | 0 | |
| Share holders equity per share | -0.02 | 0 | 0 | 0 | 0 | |
| Interest debt per share | 0.01 | 0 | 0 | 0 | 0 | |
| Market cap | 4.46M | 0 | 0 | 0 | 0 | |
| Enterprise value | 5.16M | 0 | 0 | 0 | 0 | |
| P/E ratio | 1.03 | 0 | 0 | 0 | 0 | |
| Price to sales ratio | 0 | 0 | 0 | 0 | 0 | |
| POCF ratio | -30.12 | 0 | 0 | 0 | 0 | |
| PFCF ratio | -30.12 | 0 | 0 | 0 | 0 | |
| P/B Ratio | -3.06 | 0 | 0 | 0 | 0 | |
| PTB ratio | -3.06 | 0 | 0 | 0 | 0 | |
| EV to sales | 0 | 0 | 0 | 0 | 0 | |
| Enterprise value over EBITDA | -13.63 | 0 | 0 | 0 | 0 | |
| EV to operating cash flow | -34.83 | 0 | 0 | 0 | 0 | |
| EV to free cash flow | -34.83 | 0 | 0 | 0 | 0 | |
| Earnings yield | 0.24 | 0 | 0 | 0 | 0 | |
| Free cash flow yield | -0.03 | 0 | 0 | 0 | 0 | |
| Debt to equity | -0.55 | 0 | 0 | 0 | 0 | |
| Debt to assets | 0.76 | 0 | 0 | 0 | 0 | |
| Net debt to EBITDA | -1.85 | 0 | 0 | 0 | 0 | |
| Current ratio | 0.62 | 0 | 0 | 0 | 0 | |
| Interest coverage | -914.44 | 0 | 0 | 0 | 0 | |
| Income quality | 0.37 | 0 | 0 | 0 | 0 | |
| Dividend Yield | 0 | 0 | 0 | 0 | 0 | |
| Payout ratio | 0 | 0 | 0 | 0 | 0 | |
| Sales general and administrative to revenue | 0 | 0 | 0 | 0 | 0 | |
| Research and developement to revenue | 0 | 0 | 0 | 0 | 0 | |
| Intangibles to total assets | 0 | 0 | 0 | 0 | 0 | |
| Capex to operating cash flow | 0 | 0 | 0 | 0 | 0 | |
| Capex to revenue | 0 | 0 | 0 | 0 | 0 | |
| Capex to depreciation | 0 | 0 | 0 | 0 | 0 | |
| Stock based compensation to revenue | 0 | 0 | 0 | 0 | 0 | |
| Graham number | 0.07 | 0 | 0 | 0 | 0 | |
| ROIC | -7.66 | 0 | 0 | 0 | 0 | |
| Return on tangible assets | 1.02 | 0 | 0 | 0 | 0 | |
| Graham Net | -0.03 | 0 | 0 | 0 | 0 | |
| Working capital | -655.33K | 0 | 0 | 0 | 0 | |
| Tangible asset value | -1.46M | 0 | 0 | 0 | 0 | |
| Net current asset value | -1.46M | 0 | 0 | 0 | 0 | |
| Invested capital | -0.55 | 0 | 0 | 0 | 0 | |
| Average receivables | 0 | 0 | 0 | 0 | 0 | |
| Average payables | 569.26K | 269.37K | 0 | 0 | 0 | |
| Average inventory | 0 | 0 | 0 | 0 | 0 | |
| Days sales outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days payables outstanding | 0 | 0 | 0 | 0 | 0 | |
| Days of inventory on hand | 0 | 0 | 0 | 0 | 0 | |
| Receivables turnover | 0 | 0 | 0 | 0 | 0 | |
| Payables turnover | 0 | 0 | 0 | 0 | 0 | |
| Inventory turnover | 0 | 0 | 0 | 0 | 0 | |
| ROE | -0.74 | 0 | 0 | 0 | 0 | |
| Capex per share | 0 | 0 | 0 | 0 | 0 |
RCAR Frequently Asked Questions
What is RenovaCare, Inc. stock symbol ?
RenovaCare, Inc. is a US stock , located in Scottsdale of Az and trading under the symbol RCAR
What is RenovaCare, Inc. stock quote today ?
RenovaCare, Inc. stock price is $0.0001 today.
Is RenovaCare, Inc. stock public?
Yes, RenovaCare, Inc. is a publicly traded company.
Company Profile
- Volume Average 399
- Market Capitalization 8.74K
- Employee 1
- CEO Mr. Harmel S. Rayat
- Headquarters Scottsdale,AZ,US
- IPO Date 1996-05-30
-
Website
https://www.renovacareinc.com 
RenovaCare, Inc., a development-stage biotech and medical device company, focuses on the research, development, and commercialization of autologous cellular therapies for use in medical and aesthetic applications. It is developing CellMist System, a treatment methodology for cell isolation for the regeneration of human skin cells; and SkinGun, a solution sprayer device for delivering the cells to the treatment area. RenovaCare, Inc. has a strategic collaboration StemCell Systems GmbH for isolating and spraying self-donated stem cells to regenerate tissues and organs. The company was formerly known as Janus Resources, Inc. and changed its name to RenovaCare, Inc. in January 2014. RenovaCare, Inc. is based in Scottsdale, Arizona.
